O parasita da malária Plasmodium falciparum percebe o ambiente em que se encontra, elaborando respostas celulares adequadas, que envolvem secreção de proteínas, crescimento e diferenciação celular. Fatores relacionados com a geração de segundos-mensageiros e proteínas efetoras da sinalização celular estão descritos na literatura. Porém, a função de receptores responsáveis pela percepção de estímulos extracelulares no parasita é um tema pouco explorado. A identificação in silico de receptores de sete domínios transmembrânicos putativos no genoma de P. falciparum possibilitou a exploração da função dos mesmos. A tese caracteriza funcionalmente dois receptores, PFSR10 e PFSR25. A expressão proteica dos receptores foi demonstrada em fases eritrocíticas de P. falciparum. Os receptores possuem candidatos a parceiros moleculares que executam diversas funções celulares, entre elas invasão do eritrócito, endocitose e exocitose. Os receptores foram transfectados em células de mamíferos e, através de ensaios de dinâmica de cálcio de high-throughput, sugere-se que PFSR10 codifique um receptor que participa na percepção de ATP extracelular e que PFSR25 codifique um sensor de KCl. O trabalho também sugere que KCl modula cálcio citosólico em P. falciparum e que parasitas nocaute para PFSR25 são incapazes de modular cálcio citosólico em resposta a KCl. / The malaria parasite P. falciparum perceives its milieu and elaborates adequate intracellular responses, that involve protein secretion, growth and cell differentiation. Factors related to second messengers generation and effectors of cell signaling are described in the literature. However, the function of receptors responsible for stimulus perception remains elusive. The in silico identification of putative seven transmembrane receptors in the Plasmodium falciparum genome allowed the exploration of their function. In the thesis, two putative receptors were characterized, PFSR10 and PFSR25. The proteic expression of the receptors was demonstrated in erythrocytic stages of P. falciparum. The receptors have putative interaction partners that participate in cellular functions such as invasion, exocytosis and endocytosis.The receptors were transfected in mammalian cells and, through high-throughput calcium dynamics assays, it is suggested that PFSR10 codes for a receptor that participates in extracellular ATP perception and that PFSR25 codes for a KCl sensor. It is also suggested that KCl modulates cytosolic calcium in response to KCl and that knockout parasites for PFSR25 are incapable of modulating cytosolic calcium in response to KCl.

T cell surface antigens are thought to play significant roles in immunological functions. They are involved in cellular interactions and T cell activation and proliferation. Characterization of T cell antigens is important in understanding the molecular machanisms underlying immune responses. The subject of this thesis is to characterize a novel murine T cell surface antigen called YE1/48. YE1/48, defined by two rat monoclonal antibodies YE1/48.10.6 and YE1/32.8.5, is a dimeric glycoprotein with molecular size and charge resembling the murine T cell antigen receptor α/β. It was initially detected at high levels on two T cell lymphomas, EL-4 and MBL-2. In my thesis studies, the YE1/48 antigen was characterized biochemically, a cDNA clone was isolated, and its expression in lymphoid cell populations was determined. The YE1/48 antigen was found to be distinct from the T cell receptor based on direct comparisons of their primary sequences as well as immunological analyses. It is likely a homodimer with similar or identical subunits. No homology with any known proteins could be detected, including the human T cell activation antigen CD28 (T44) which also has a similar dimeric structure as YE1/48. No function of the YE1/48 antigen could be derived from its primary sequence or with the use of the two monoclonal antibodies because the antibodies do not appear to bind to the surface of intact normal T lymphocytes. Some intriguing characteristics of the YE1/48 antigen were observed in the current studies. The YE1/48 antigen belongs to a rare group of type II membrane proteins with orientation of the amino-terminus inside the cell and the carboxy-terminus outside. The YE1/48 gene may have two alleles among different mouse strains and may belong to a multigene family. YE1/48 is expressed at low levels on a wide range of T cells with no restriction to their differentiation stages, and on spleen B cells as well as bone marrow cells. Its expression on lymphocytes is not related to activation or proliferation. However, YE1/48 expression appears to be induced at high levels by Abelson Murine Leukemia Virus-transformation of pre-B cells. Moreover, the epitopes defined by the YE1/48.10.6 and YE1.32.8.5 antibodies seem to be exposed only on three T lymphomas but not on normal T cells. It is thus tantalizing to speculate a correlation of the high level expression of YE1/48 antigen and its epitope exposure on transformed lymphocytes with cellular transformation. In summary, YE1/48 was found to be a novel T cell surface antigen which has similar dimeric structure as the murine T cell receptor α/β and human CD28 (T44). It has now been characterized biochemically, molecularly cloned, and its expression on lymphoid cells has been determined. Although the function of YE1/48 antigen remains unknown, a number of intriguing characteristics observed in the current studies have certainly called for further studies on the antigen and the determination of its function. / Science, Faculty of / Microbiology and Immunology, Department of / Graduate

Cancer vaccines represent a promising treatment modality for a world-wide health problem. Whether as an adjuvant or as a stand-alone therapy, cancer vaccines represent a tumor-specific and systemic treatment potentially capable of eliminating metastatic lesions without the severe side-effects often associated with chemotherapy. Specifically, whole cell tumor vaccines have shown promise in preclinical and clinical settings and the studies presented here represent the beginnings of an approach to improve the antitumor potency of these vaccines. This project demonstrates as "proof of concept" the feasibility of manufacturing tumor cell-particle hybrids. The coupled use of these two components, whole tumor cells and cargo-carrying biodegradable particles, as one entity in a cancer vaccine system is a new line of research. Stable cell-particle hybrids were assembled using avidin-biotin chemistry where cargo-carrying PLGA particles (500 nm diameter) were coated with streptavidin and allowed to bind to tumor cells that had been indirectly labeled with biotin (using an integrin-specific biotinylated antibody). That successful cell-particle hybrids were assembled was determined by multiple means, including flow cytometry, laser scanning confocal microscopy and scanning electron microscopy. Two murine tumor cell lines (representing melanoma and prostate cancer) were investigated in this study and successfully demonstrated the general applicability of the assembly method. Particles appeared to be localized on the cell surface (rather than endocytosed) as determined by microscopic imaging. The cell-particle hybrid was shown to be stable to irradiation, an important consideration since whole tumor cells need to be treated with ionizing radiation prior to being used as vaccines in order to render them nonproliferative and immunogenic. We also characterized loading and release profiles of CpG, a prospective vaccine adjuvant, into PLGA particles. We conclude that we have developed a method for manufacturing cell-particle hybrids comprising PLGA nanoparticles and irradiated tumor cells. The next step would be to use CpG-loaded particles in the assembled hybrid and test the anti-tumor immune efficiency of this cancer vaccine formulation in either a melanoma or prostate cancer model.

Un être humain adulte produit environ deux millions d’érythrocytes par seconde, à travers un processus connu sous le nom d’érythropoïèse. L’érythropoïèse est contrôlée par une balance entre prolifération et différenciation finement régulée. L’expression des gènes impliqués dans ces deux processus distincts, est régulée extrinsèquement (cytokines) et intrinsèquement (microenvirennement métabolique, facteurs de transcription). Les facteurs de transcription, fonctionnent sous forme de complexes multiprotéiques et contrôlent l’activité transcriptionnelle des cellules. Parmi eux, le complexe LDB1 joue un rôle clé dans la régulation de la balance prolifération/différenciation pendant l’érythropoïèse, puisqu’il contrôle l’expression des gènes impliquées dans ces deux processus. Au cours de mon doctorat, nous avons d’abord caractérisé les mécanismes moléculaires de la “pré-activation” des gènes de différenciation, également nommés marqueurs erythroides, dans les progéniteurs erythroides immatures. La pré-activation, est un état dans lequel, les gènes sont exprimés à un niveau basal très bas, permissif pour une activation significative pendant la différenciation. Nous avons ainsi montré que les répresseurs : ETO2, IRF2BP2 et NCOR1, interagissent avec le complexe LDB1, et lient ensemble les gènes des marqueurs erythroides et les répriment. Au cours de l’érythropoïèse, ces corépresseurs sont déstabilisés et LDB1 agit alors comme un activateur. En ce qui concerne les gènes de prolifération, nous avons observé que le complexe LDB1 est déstabilisé au niveau de ces loci pendant l’érythropoïèse. Afin d’étudier les mécanismes moléculaires de la répression génique des gènes de prolifération au cours de l’érythropoïèse, nous avons choisi d’étudier Myb, une cible du complexe LDB1, étudié auparavant dans le laboratoire. Nous avons testé trois facteurs : ZEB1, OGT et RNF12, en tant que candidats dans la répression de Myb. Nous avons montré que RNF12 est le seul facteur intervenant dans la transcription de Myb. RNF12 régule Myb probablement par une modification de complexes épigénétiques. / Every second about 2 million erythrocytes are produced in the adult human body, through a process called erythropoiesis. Erythropoiesis is controlled by a highly regulated balance between proliferation and differentiation. Expression of genes responsible for cell proliferation and differentiation is controlled external (such as cytokines) and internal (such as metabolic microenvironment and transcription factors). Transcription factors bind DNA and recruit co-factors generating transcriptional complexes. The LDB1 complex has a key role in the balance between erythroid proliferation vs. differentiation, since it regulates genes involved in both processes. During my Ph.D., we investigated the molecular mechanisms that LDB1 employs to regulate genes with divergent function. We first showed that in erythroid progenitors, differentiating genes, also known as erythroid markers, are primed. Gene priming consists of genes expressed in low basal but significant levels in progenitors, which can rapidly be activated during differentiation. We showed that in progenitors, ETO2, IRF2BP2 and NCOR1, bind the LDB1 complex therefore generating a priming complex. During differentiation, binding of the repressive (ETO2-IRF2BP2-NCOR1) co-factors to the LDB1 complex, is destabilized and genes become active. In genes involved in erythroid proliferation, we observed that LDB1 is destabilized, a feature leading to gene silencing. We used Myb, as a model of gene silencing in the context of regulation by the LDB1 complex. We tested three transcription factors: ZEB1, OGT and RNF12, as candidates in gene silencing. Among these factors, only RNF12 regulates Myb expression, probably through modifications of epigenetic silencers (Polycomb/MLL).

Colorectal cancer (CRC) is one of the deadliest cancers in the world. The early stage of the disease is usually asymptomatic and therefore screening methods for colorectal cancer need to improve. There is a need for early detection of CRC as treatment is less effective in the advanced stage of the disease.  The current standard screening methods are endoscopy and fecal immunochemical blood tests. Endoscopy is a commonly used method to diagnose the patient, but it is costly, time consuming, and rather unpopular for the patients. An alternative could be to develop targeted molecular imaging probes that specifically deliver agents for example magnetic resonance imaging to colon adenomas and adenocarcinomas. This alternative would be non-invasive and able to detect the disease before morphological changes become evident. Biomarkers are used as an objective indicator of an altered biological process. Here, a literature study was conducted to identify protein biomarkers that are overexpressed in early stages of CRC. This study has focused on biomarkers that could be used to target imaging agents to cancerous lesions. Thus, the biomarkers need to be membrane-bound and expressed on the luminal side of the gastrointestinal tract. This will help future research to develop orally administered targeted imaging probes. Furthermore, a smaller literature search was conducted to identify cell and mouse models representing early stages of CRC. This was done to facilitate translational research going from in vitro to in vivo. Ideally the same protein is available in cell lines, mouse models and humans to enable translational research. This work has resulted in the selection of 7 different proteins that are upregulated during early stages of CRC. These proteins are potentially apically located and therefore possible targets for monoclonal antibodies. These findings might lead to a novel way for preventive patient screening and hopefully reduce the mortality for colorectal cancer.

Recognition ofmicrobial products by germ-line-encoded PRR initiates immune responses, but how PRR mediate specific host responses to infectious agents is poorly understood. We and others have proposed that specificity is achieved by collaborative responsesmediated between different PRR. One such example comprises the fungal β-glucan receptor Dectin-1, which collaborates with TLR to induce TNF production. We show here that collaborative responses mediated by Dectin-1 and TLR2 are more extensive than first appreciated, and result in enhanced IL-23, IL-6 and IL-10 production in DC, while down-regulating IL-12 relative to the levels produced by TLR ligation alone. Such down-regulation occurred with multiple MyD88-coupled TLR, was dependent on signaling through Dectin-1 and also occurred in macrophages. These findings explain how fungi can induce IL-23 and IL-6, while suppressing IL-12, a combination which has previously been shown to contribute to the development of Th17 responses found during fungal infections. Furthermore, these data reveal how the collaboration of different PRR can tailor specific responses to infectious agents.

Microglia are the resident innate immune cells that are critical for innate and adaptive immune responses within the CNS. They recognize and are activated by pathogen-associated molecular patterns (PAMPs) present on the surface of pathogens. β-glucans, the major PAMP present within fungal cell walls, are recognized by Dectin-1, which mediates numerous intracellular events invoked by β-glucans in various immune cells. Previously, we showed that Dectin-1 mediates phagocytosis of β-glucan and subsequent superoxide production in microglia. Here, we report that the guanine nucleotide exchange factor Vav1 as well as phosphoinositide-3 kinase (PI3K) are downstream mediators of what is now recognized as the Dectin-1 signaling pathway. Both Vav1 and PI3K are activated upon stimulation of microglia with β-glucans, and the two proteins are required for phagocytosis of the glucan particles and for subsequent superoxide production. We also show that Vav1 functions upstream of PI3K and is required for activation of PI3K. Together, our results provide an important insight into the mechanistic aspects of microglial activation in response to β-glucans.

Microglia, the resident immune cells of the brain, are activated in response to any kind of CNS injury, and their activation is critical for maintaining homeostasis within the CNS. However, during inflammatory conditions, sustained microglial activation results in damage to surrounding neuronal cells. β-Glucans are widely recognized immunomodulators, but the molecular mechanisms underlying their immunomodulatory actions have not been fully explored. We previously reported that β-glucans activate microglia through Dectin-1 without inducing significant amount of cytokines and chemokines. Here, we show that particulate β-glucans attenuate cytokine production in response to TLR stimulation; this inhibitory activity of β-glucan is mediated by Dectin-1 and does not require particle internalization. At the molecular level, β-glucan suppressed TLR-mediated NF-κB activation, which may be responsible for the diminished capacity of microglia to produce cytokines in response to TLR stimulation. Overall, these results suggest that β-glucans may be used to prevent or treat excessive microglial activation during chronic inflammatory conditions.

京都大学 / 0048 / 新制・課程博士 / 博士(農学) / 甲第17793号 / 農博第2014号 / 新制||農||1016(附属図書館) / 学位論文||H25||N4784(農学部図書室) / 30600 / 京都大学大学院農学研究科応用生物科学専攻 / (主査)教授 今井 裕, 教授 久米 新一, 教授 松井 徹 / 学位規則第4条第1項該当 / Doctor of Agricultural Science / Kyoto University / DFAM

京都大学 / 0048 / 新制・課程博士 / 博士(農学) / 甲第18331号 / 農博第2056号 / 新制||農||1022(附属図書館) / 学位論文||H26||N4838(農学部図書室) / 31189 / 京都大学大学院農学研究科応用生命科学専攻 / (主査)教授 植田 充美, 教授 三上 文三, 教授 小川 順 / 学位規則第4条第1項該当 / Doctor of Agricultural Science / Kyoto University / DFAM